3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Colorectal Neoplasms
32
Colonic Neoplasms
20
Rectal Neoplasms
11
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Stomach Neoplasms
2
Neoplastic Cells, Circulating
2
Neoplasms
2
Liver Neoplasms
2
Recurrence
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Oligometastatic Gastric Adenocarcinoma
1
Neuroendocrine Tumors
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Recurrence, Local
1
Margins of Excision
1
Locally Advanced Rectal Cancer
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gallbladder Neoplasms
1
Cholangiocarcinoma
1
Biliary Tract Neoplasms
1
Interventions
Everolimus
6
lutetium Lu 177 dotatate
5
lanreotide
4
Octreotide
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
amino-acid, glucose, and electrolyte solution
3
Capecitabine
3
surufatinib
2
fluorodopa F 18
2
Introns
2
telotristat ethyl
1
copper dotatate CU-64
1
cabozantinib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Specimen Handling
1
Somatostatin
1
Serotonin
1
Salts
1
Phantoms, Imaging
1
Oxaliplatin
1
Magnetic Resonance Spectroscopy
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Interferon alpha-2
1
Immunoglobulin G
1
Ga(III)-DOTATOC
1
Furosemide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neuroendocrine Tumors
×
Folfox protocol
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled